Category Archives: Deals
By Guest Blogger | Published: October 31, 2012
By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
By Ben Comer | Published: August 7, 2012
The sun was shining, savory scents were floating out from the grill, the lemonade was mixed and the table was set. But then dark clouds blew in and settled overhead. Bristol-Myers Squibb’s (BMS) picnic got rained out this summer. One element of the rain out was forecasted long ago; Plavix, the multibillion dollar blood-thinner, second […]
By Guest Blogger | Published: June 17, 2012
Final: THE COST OF PHARMA DIVORCE Corporate spin-offs are on the rise across the pharmaceutical sector, but at what cost to shareholders? Brian McGilligan, AVP, Life Sciences Program Management Consulting Lead at Cognizant argues that in haste to obtain decree absolute, demerging businesses could be threatening their long term viability. Demergers are in fashion again. […]
By Guest Blogger | Published: April 25, 2012
By Patricia Van Arnum. Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share. Although rejecting GSK’s initial bid, HGS kept the door open for other suitors, including again GSK. HGS has authorized its board of directors to explore strategic alternatives for the company, including a […]